Comparison of semi-automated and manual methods to measure the volume of prostate cancer on magnetic resonance imaging

Marin, Laura; Ezziane, Malek; Compérat, Éva; Mozer, Pierre; Cancel‐Tassin, Géraldine; Côté, Jean‐François; Racoceanu, Daniel; Lucidarme, O.; Cussenot, Olivier; Penna, R. Renard

doi:10.1016/j.diii.2017.02.004

Cited by 17 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(Ukimura et al, 2013) Multiparametric MRI is increasingly used in prostate cancer assessment for its diagnosis and detection and for staging and risk stratification (Thompson, Lawrentschuk, Frydenberg, Thompson, & Stricker, 2013;Felker, Margolis, Nassiri, & Marks, 2016). A concern regarding mpMRI is the considerable interobserver variability (Fedorov, Vangel, Tempany, & Fennessy, 2017;Marin et al, 2017). Mp-MRI has been used to assess prostate cancer aggressiveness and to identify anteriorly located tumors before and during active surveillance.…”

Section: Introductionmentioning

confidence: 99%

Correlation Between mpMRI Staging and Final Surgical Pathology in Prostate Cancer

Lashay¹,

Gholivandan²,

Sehri³

et al. 2020

JMBR

View full text Add to dashboard Cite

Purpose: We evaluated the role of multiparametric magnetic resonance imaging (mpMRI) in the diagnosis of prostate cancer and predicting of surgical staging of prostate cancer. Materials and Methods: The study was done in 110 subjects who got mpMRI before radical prostatectomy in our hospital from 2016 to 2019. Preoperative mpMRI findings of 110 were compared to surgical pathology results following radical Prostatectomy. A comparison was made between pathologic staging of prostate cancer and the mpMRI findings. Results: pathologic evaluation confirmed prostate cancer foci (237) were recognized in 110 subjects. Generally, mpMRI sensitivity of 46.4% was found for prostate cancer detection (110/237). Pathological tumor volume was a significant predictor of prostate cancer detection using mpMRI. In 33% of the cases, the pathologic staging is precisely similar to mpMRI and in 43%of the cases, there was a slight difference between the pathologic staging and staging by mpMRI but the cancer was confined to the prostate.in 24% of the cases, there was a significant difference between the pathologic staging and staging by mpMRI. The mpMRI was not able to identify the significant cancer in 24% of the cases. Conclusion: The preoperative mpMRI was useful in detecting prostate cancer and in predicting surgical staging. However, the detection of 24% of clinically significant cancer was missed using mpMRI. As we move toward personalized medicine, use of MRI to biopsy each man's prostate differently rather than based on a pre-defined 12 core seems to be supported in the recent literature.

show abstract

Section: Introductionmentioning

confidence: 99%

Correlation Between mpMRI Staging and Final Surgical Pathology in Prostate Cancer

Lashay¹,

Gholivandan²,

Sehri³

et al. 2020

JMBR

View full text Add to dashboard Cite

show abstract

“…More specifically, the apparent diffusion coefficient, which is calculated from DWI sequences, inversely correlates with PCa aggressiveness ( 18 ). Furthermore, automated calculations of lesion volume on mpMRI reliably correspond with PCa presence ( 18 , 20 ). Marin et al demonstrated that the use of semi-automated sizing algorithms to measure maximal tumor dimensions of suspicious lesions reliably correlated with actual tumor histologic diameter, and this practice should be considered during routine workup ( 20 ).…”

Section: Resultsmentioning

confidence: 92%

Prostate Cancer Imaging and Biomarkers Guiding Safe Selection of Active Surveillance

et al. 2017

View full text Add to dashboard Cite

BackgroundActive surveillance (AS) is a widely adopted strategy to monitor men with low-risk, localized prostate cancer (PCa). Current AS inclusion criteria may misclassify as many as one in four patients. The advent of multiparametric magnetic resonance imaging (mpMRI) and novel PCa biomarkers may offer improved risk stratification. We performed a review of recently published literature to characterize emerging evidence in support of these novel modalities.MethodsAn English literature search was conducted on PubMed for available original investigations on localized PCa, AS, imaging, and biomarkers published within the past 3 years. Our Boolean criteria included the following terms: PCa, AS, imaging, biomarker, genetic, genomic, prospective, retrospective, and comparative. The bibliographies and diagnostic modalities of the identified studies were used to expand our search.ResultsOur review identified 222 original studies. Our expanded search yielded 244 studies. Among these, 70 met our inclusion criteria. Evidence suggests mpMRI offers improved detection of clinically significant PCa, and MRI-fusion technology enhances the sensitivity of surveillance biopsies. Multiple studies demonstrate the promise of commercially available screening assays for prediction of AS failure, and several novel biomarkers show promise in this setting.ConclusionIn the era of AS for men with low-risk PCa, improved strategies for proper stratification are needed. mpMRI has dramatically enhanced the detection of clinically significant PCa. The advent of novel biomarkers for prediction of aggressive disease and AS failure has shown some initial promise, but further validation is warranted.

show abstract

“…Results are shown in Tables 1–5. Table 1 lists the 18 studies and shows the accuracy calculation 19,23–39 . This determined the order of the studies as presented in the remaining Tables 2–5.…”

Section: Resultsmentioning

confidence: 99%

How accurately can multiparametric magnetic resonance imaging measure the tumour volume of a prostate cancer? Results of a systematic review

Christie

Sharpley

2020

J Med Imag Rad Onc

View full text Add to dashboard Cite

Summary The tumour volume of a cancer within the prostate gland is commonly measured with multiparametric MRI. The measurement has a role in many clinical scenarios including focal therapy, but the accuracy of it has never been systematically reviewed. We included articles if they compared tumour volume measurements obtained by mpMRI with a reference volume measurement obtained after radical prostatectomy. Correlation and concordance statistics were summarised. A simple accuracy score was derived by dividing the given mean or median mpMRI volume by the histopathological reference volume. Factors affecting the accuracy were noted. Scores for potential bias and quality were calculated for each article. A total of 18 articles describing 1438 patients were identified. Nine articles gave Pearson’s correlation scores, with a median value of 0.75 but the range was wide (0.42–0.97). A total of 11 articles reported mean values for volume while 9 reported median values. For all 18 articles, the mean or median values for MRI volumes were lower than the corresponding reference values suggesting consistent underestimation. For articles reporting mean and median values for volume, the median accuracy scores were 0.83 and 0.80, respectively. The accuracy was higher for tumours of greater volume, higher grade and when an endorectal coil was used. Accuracy did not seem to improve over time, with a 3 Tesla magnet or by applying a shrinkage factor to the reference measurement. Most studies showed evidence of at least moderate bias, and their quality was highly variable, but neither of these appeared to affect accuracy.

show abstract

Comparison of semi-automated and manual methods to measure the volume of prostate cancer on magnetic resonance imaging

Cited by 17 publications

References 22 publications

Correlation Between mpMRI Staging and Final Surgical Pathology in Prostate Cancer

Correlation Between mpMRI Staging and Final Surgical Pathology in Prostate Cancer

Prostate Cancer Imaging and Biomarkers Guiding Safe Selection of Active Surveillance

How accurately can multiparametric magnetic resonance imaging measure the tumour volume of a prostate cancer? Results of a systematic review

Contact Info

Product

Resources

About